News
Public · Published
ArriVent BioPharma, Inc. Stock 12‑Month Price Target Raised to $24, Implies 14% Upside
The average 12-month price target for ArriVent BioPharma stock rose from $22.91 to $24 across 11 analysts, with forecasts ranging from $15 to $30. Based on the Oct. 23 closing price, the new target implies about 14% potential upside.
Published:
Updated:
What happened
The average 12-month price target for ArriVent BioPharma stock rose from $22.91 to $24 across 11 analysts, with forecasts ranging from $15 to $30. Based on the Oct. 23 closing price, the new target implies about 14% potential upside.
Confirmed
Global impact / market context
A higher average target means analysts on balance expect more gains ahead, which can draw buyer interest and support the share price. The all-Buy consensus shows strong confidence, but targets still range widely from $15 to $30, so views differ.
Analyst inference
Analyst targets are average expectations, not guarantees, and can change quickly after trial results or financial reports. The 14% upside figure depends on the Oct. 23 closing price, so the implied gain shifts as the stock moves.
Analyst inference
What to watch
- Watch whether the average target keeps rising, since it moved from $22.91 to $24, and whether the $15 to $30 range narrows as analysts update their views. Confirmed
- Watch for new analyst notes that change ratings away from the current all-Buy consensus of 12 Buys, 0 Holds and 0 Sells, as any downgrade would shift the average target. Proposed
- Watch company updates such as trial results or financial reports, which could prompt analysts to revise targets and test whether the implied 14% upside holds. Analyst inference
Evidence
- Original source link unavailable